

REMARKS

Reconsideration and allowance of the application are respectfully requested in light of the foregoing amendments and the following remarks.

Claims 76-106 and 108-110 are pending in the application. Claims 76-87, 90-93, 96-98, 100-106 and 108-110 are canceled herein without prejudice or disclaimer. Claims 88, 89, 94, 95 and 99 have been re-written in independent format, as helpfully suggested by the Examiner. Entry of the foregoing amendments is respectfully requested.

Claims 76-87, 90-93, 96-98, 100-106 and 108-110 were rejected under 35 U.S.C. §112, first paragraph, for lack of enablement. It is believed that this rejection is now rendered moot by the cancellation of the aforesaid claims. This action is taken to expedite allowance, and in no way should be construed as an acquiescence to the alleged merits of the rejection.

Claims 88, 89, 94, 95 and 99 were objected to, with the Office indicating allowable subject matter was contained therein. In response, these claims have each been re-written in independent format to incorporate the salient features of the intervening claims 76 and 77. Accordingly, applicants respectfully request withdrawal of the objection

The application is believed to be in proper condition of allowance, and prompt, favorable action thereon is earnestly solicited. Should Examiner Balasubramanian feel that any other point requires consideration, then he is cordially invited to contact the undersigned.

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000

/john f levis/  
John F. Levis  
Attorney for Applicants  
Reg. No. 34,210  
Phone: 203-677-3782  
Date: August 23, 2007